Search | Clinical Trials Finder

Conditions: Coronary Artery Disease
Interventions: Methotrexate, Colchicine, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Rheumatoid Arthritis
Interventions: Placebo, JNJ-38518168 (3 mg), JNJ-38518168 (10 mg), JNJ-38518168 (30 mg), Methotrexate; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 9
States / cities: Huntsville, Alabama • Gilbert, Arizona • Covina, California + 6 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Methotrexate, Abatacept placebo, Methotrexate placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 15
States / cities: Huntsville, Alabama • Hot Springs, Arkansas • Sarasota, Florida + 12 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB), Infliximab (INF) + MTX, DB, Placebo (PLA) + MTX, DB, PLA + MTX switched to ABA+ MTX, DB, ABA, open-label (OL); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 431 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 19
States / cities: Huntsville, Alabama • Denver, Colorado • Boca Raton, Florida + 16 more

Conditions: Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases
Interventions: Golimumab 50 mg SC, Golimumab 2 mg/kg IV, Methotrexate (MTX), Placebo SC, Placebo IV; Drug
Lead sponsor: Janssen Biotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 89
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 86 more

Conditions: Rheumatoid Arthritis
Interventions: GDC-0853, Adalimumab, Folic Acid, MTX, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 23
States / cities: Anniston, Alabama • Glendale, Arizona • Covina, California + 18 more

Conditions: Rheumatoid Arthritis
Interventions: Sarilumab, Placebo (for sarilumab), Methotrexate, Folic Acid; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 45
States / cities: Anniston, Alabama • Birmingham, Alabama • Gilbert, Arizona + 39 more

Conditions: Rheumatoid Arthritis
Interventions: ATI-450 50 mg oral tablet BID, Placebo oral tablet, Methotrexate, ATI-450 20 mg oral tablet BID; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 11
States / cities: El Cajon, California • Encino, California • La Jolla, California + 8 more

Conditions: Rheumatoid Arthritis
Interventions: ATI-450, Placebo oral tablet, Methotrexate; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: Anniston, Alabama • Tampa, Florida • Atlanta, Georgia + 2 more

Conditions: Rheumatoid Arthritis
Interventions: natalizumab, placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 10
States / cities: Birmingham, Alabama • Tucson, Arizona • Escondido, California + 7 more

Conditions: Rheumatoid Arthritis
Interventions: ALX-0061, Placebo, Methotrexate; Biological · Other · Drug
Lead sponsor: Ablynx, a Sanofi company; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 22
States / cities: Birmingham, Alabama • Hemet, California • La Palma, California + 18 more

Conditions: Psoriasis
Interventions: adalimumab, MTX, placebo adalimumab, placebo MTX; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Abbott Park, Illinois

Conditions: Active Rheumatoid Arthritis
Interventions: Tranilast, Placebo; Drug
Lead sponsor: Nuon Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Mesa, Arizona • Paradise Valley, Arizona • La Jolla, California + 6 more

Conditions: Rheumatoid Arthritis
Interventions: Humax-CD4, Placebo; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 50
States / cities: Montgomery, Alabama • Long Beach, California • Rancho Cucamonga, California + 45 more

Conditions: Gout
Interventions: Pegloticase, methotrexate, placebo, folic acid, gout flare prophylaxis regimen, fexofenadine, acetaminophen, methylprednisolone; Biological · Drug · Dietary Supplement
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 60
States / cities: Birmingham, Alabama • Anchorage, Alaska • Flagstaff, Arizona + 54 more

Conditions: Rheumatoid Arthritis
Interventions: Adalimumab, Placebo; Biological · Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 76
States / cities: Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more

Conditions: Arthritis, Rheumatoid
Interventions: LY2127399, Placebo; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 19
States / cities: Birmingham, Alabama • Mesa, Arizona • Palm Desert, California + 16 more

Conditions: Rheumatoid Arthritis
Interventions: Baricitinib, Methotrexate, Baricitinib Placebo, MTX Placebo, Folic Acid; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 47
States / cities: Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 44 more

Conditions: Rheumatoid Arthritis
Interventions: Upadacitinib, Adalimumab, Upadacitinib Matching Placebo, Adalimumab Matching Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 487 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 85
States / cities: Flagstaff, Arizona • Glendale, Arizona • Peoria, Arizona + 75 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 12
States / cities: Hemet, California • DeBary, Florida • Venice, Florida + 9 more

Conditions: Rheumatoid Arthritis
Interventions: Tasocitinib plus Methotrexate, Tofacitinib plus placebo methotrexate, Placebo tofacitinib plus Methotrexate; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 8
States / cities: Gilbert, Arizona • Huntington Beach, California • Upland, California + 5 more

Conditions: Ulcerative Colitis
Interventions: Methotrexate; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 70 Years
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 31
States / cities: Los Angeles, California • Denver, Colorado • Winter Park, Florida + 26 more

Conditions: Rheumatoid Arthritis
Interventions: Sarilumab, Etanercept, Methotrexate, Placebo (for sarilumab), Placebo (for etanercept), Adalimumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 776 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 30
States / cities: Birmingham, Alabama • Glendale, California • Thousand Oaks, California + 27 more

Conditions: Rheumatoid Arthritis (RA)
Interventions: AP1189, 40 mg, AP1189, 70 mg, AP1189, 100 mg, AP1189 matching placebo; Drug
Lead sponsor: SynAct Pharma Aps; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Cutler Bay, Florida • Miami, Florida • Duncansville, Pennsylvania

Search by objective public record fields.

Inflammation and Coronary Endothelial Function

A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis

Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis

Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)

Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)

Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients

ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)

Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA

Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate

A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis

Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Safety and Efficacy Study of Tranilast in Patients With Active Rheumatoid Arthritis (RA)

Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker

Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout

Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.

A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone

Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)

Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis

An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate

A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis